Edition:
United Kingdom

Fresenius SE & Co KGaA (FREG.DE)

FREG.DE on Xetra

65.70EUR
4:35pm BST
Change (% chg)

€-0.26 (-0.39%)
Prev Close
€65.96
Open
€66.04
Day's High
€66.30
Day's Low
€65.44
Volume
1,495,452
Avg. Vol
1,516,244
52-wk High
€80.07
52-wk Low
€58.96

Select another date:

Tue, Mar 27 2018

Photo

Fresenius spokesman says probe into target Akorn continues

FRANKFURT Fresenius said on Tuesday its investigation into potential breaches of U.S. Food and Drug Administration data requirements at takeover target Akorn was ongoing.

Fresenius spokesman says probe into target Akorn continues

FRANKFURT, March 27 Fresenius said on Tuesday its investigation into potential breaches of U.S. Food and Drug Administration data requirements at takeover target Akorn was ongoing.

CORRECTED-UPDATE 1-Akorn settles U.S. SEC claims stemming from financial restatement

March 26 Akorn Inc and two former executives have agreed to settle claims stemming from inaccurate financial statements the generic drugmaker issued in 2014 that it later needed to restate, the U.S. Securities and Exchange Commission on Monday said.

BRIEF-Fresenius CEO Says Needs Support And Data From Akorn For Analysis

* FRESENIUS CEO SAYS NEEDS SUPPORT AND DATA FROM AKORN FOR ANALYSIS Further company coverage:

BRIEF-Fresenius CEO: May Not Seek New U.S. Deal If Akorn Falls Through

Feb 27 Fresenius Se & Co Kgaa CEO at news conference:

Fresenius may back out of Akorn deal if probe finds breaches

BAD HOMBURG, Germany Fresenius may back out of the planned acquisition of Akorn if its probe into data integrity at the U.S. maker of liquid generic drugs yields evidence of wrongdoing, the German healthcare group's chief executive said.

Fresenius may back out of Akorn deal if probe finds breaches

BAD HOMBURG, Germany Fresenius may back out of the planned acquisition of Akorn if its probe into data integrity at the U.S. maker of liquid generic drugs yields evidence of wrongdoing, the German healthcare group's chief executive said.

Fresenius says probe may affect Akorn deal, sees slower 2018 sales

BERLIN German healthcare group Fresenius SE has raised doubts about its planned acquisition of Akorn because of a probe into data integrity at the U.S. maker of liquid generic drugs.

Fresenius says probe may affect Akorn deal, sees slower 2018 sales

BERLIN German healthcare group Fresenius SE has raised doubts about its planned acquisition of Akorn because of a probe into data integrity at the U.S. maker of liquid generic drugs.

Fresenius may back out of Akorn deal if probe finds breaches

BAD HOMBURG, Germany, Feb 27 Fresenius may back out of the planned acquisition of Akorn if its probe into data integrity at the U.S. maker of liquid generic drugs yields evidence of wrongdoing, the German healthcare group's chief executive said.

Select another date: